Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Adjuvant Chemotherapy for Pancreatic Cancer
share announcement

Adjuvant Chemotherapy for Pancreatic Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 October 2023) | Viewed by 996

Special Issue Editor

Prof. Dr. Keiichi Kubota

E-Mail Website
Guest Editor
Tohto Bunkyo Hospital, Bunkyo City, Tokyo 113-0034, Japan
Interests: hepatocellular carcinoma; cholangiocarcinoma; pancreatic cancer; hepatic resection; intraductal papillary neoplasm of the bile duct; pancreatectomy

Special Issue Information

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) is one of the major causes of cancer-related mortality worldwide. Although curative resection is desired for long-term survival rates from PDAC, even after surgery, survival rates remain low. To improve prognosis after surgery, adjuvant chemotherapy is mandatory. There are several treatment ways available, such as S1, gemcitabine, gemcitabine + capecitabine, gemcitabine + nab-paclitaxel and FOLFIRINOX. However, there is insufficient evidence regarding the selection of drugs and optimal duration of adjuvant chemotherapy. Furthermore, in addition to tools which are available now, diagnostic methods for detection of recurrence are required. Liquid biopsy and circ RNAs may be able to detect recurrence at an earlier stage. In this Special Issue on “Adjuvant Chemotherapy for Pancreatic Cancer”, recent advances in adjuvant chemotherapy are discussed.

Prof. Dr. Keiichi Kubota
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • pancreatic ductal adenocarcinoma
  • adjuvant chemotherapy
  • pancreatic resection
  • neoadjuvant chemotherapy
  • hyperthermia
  • curative resection
  • recurrence
  • S1
  • gemcitabine

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 567 KiB  
Review
Neoadjuvant and Adjuvant Chemotherapy for Pancreatic Adenocarcinoma: Literature Review and Our Experience of NAC-GS
by Taku Aoki, Shozo Mori and Keiichi Kubota
Cancers 2024, 16(5), 910; https://doi.org/10.3390/cancers16050910 - 23 Feb 2024
Viewed by 702
Abstract
In addition to established evidence of the efficacy of adjuvant chemotherapy (AC) for pancreatic ductal adenocarcinoma (PDAC), evidence of the effects of neoadjuvant treatments (NATs), including chemotherapy and chemoradiotherapy, has also been accumulating. Recent results from prospective studies and meta-analyses suggest that NATs [...] Read more.
In addition to established evidence of the efficacy of adjuvant chemotherapy (AC) for pancreatic ductal adenocarcinoma (PDAC), evidence of the effects of neoadjuvant treatments (NATs), including chemotherapy and chemoradiotherapy, has also been accumulating. Recent results from prospective studies and meta-analyses suggest that NATs may be beneficial not only for borderline resectable PDAC, but also for resectable PDAC, by increasing the likelihood of successful R0 resection, decreasing the likelihood of the development of lymph node metastasis, and improving recurrence-free and overall survival. In addition, response to NAT may be informative for predicting the clinical course after preoperative NAT followed by surgery; in this way, the postoperative treatment strategy can be revised based on the effect of NAT and the post-neoadjuvant therapy/surgery histopathological findings. On the other hand, the response to NAT and AC is also influenced by the tumor biology and the patient’s immune/nutritional status; therefore, planning of the treatment strategy and meticulous management of NAT, surgery, and AC is required on a patient-by-patient basis. Our experience of using gemcitabine plus S-1 showed that this NAT regimen achieved tumor shrinkage and decreased the levels of tumor markers but failed to provide a survival benefit. Our results also suggested that response/adverse events to NAT may be predictive of the efficacy of AC, as well as survival outcomes. Full article
(This article belongs to the Special Issue Adjuvant Chemotherapy for Pancreatic Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop